Darbesis
Generic Name
Darbepoetin Alfa
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| darbesis 60 mcg injection | ৳ 5,505.00 | N/A |
Description
Overview of the medicine
Darbesis-60 mcg Injection contains Darbepoetin Alfa, a synthetic erythropoiesis-stimulating agent (ESA) that stimulates red blood cell production. It is primarily used to treat anemia associated with chronic kidney disease (CKD) in both dialysis and non-dialysis patients, and also anemia in cancer patients receiving chemotherapy.
Uses & Indications
Dosage
Adults
Initial dose typically 0.45 mcg/kg subcutaneously or intravenously once weekly, or 0.75 mcg/kg once every two weeks. Adjusted to achieve target hemoglobin.
Elderly
No specific dose adjustment generally required, but close monitoring is advised due to potential comorbidities.
Renal_impairment
Used to treat anemia in CKD patients; dosage is adjusted based on hemoglobin levels and individual response.
How to Take
Administered by subcutaneous (SC) injection or intravenous (IV) injection. IV administration is preferred for patients on hemodialysis. SC administration may be preferred for patients not on hemodialysis.
Mechanism of Action
Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. It interacts with the erythropoietin receptor on progenitor cells in the bone marrow to stimulate red blood cell production and maturation. Its longer half-life compared to epoetin alfa allows for less frequent dosing.
Pharmacokinetics
Onset
Reticulocyte count increases within 7-10 days, hemoglobin rise is gradual over several weeks.
Excretion
Cleared primarily by erythrocyte uptake and subsequent degradation, with minimal renal excretion of the intact drug.
Half life
Approximately 49 hours (SC) to 21 hours (IV) in CKD patients.
Absorption
Administered subcutaneously (SC) or intravenously (IV). Bioavailability after SC administration is approximately 37% in CKD patients.
Metabolism
Primarily catabolized through non-renal pathways; minimal hepatic metabolism.
Side Effects
Contraindications
- •Uncontrolled hypertension
- •Pure Red Cell Aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs
- •Known serious allergic reaction to darbepoetin alfa or any excipients
Drug Interactions
Other ESAs
Concomitant use with other ESAs is not recommended.
Cyclosporine
Co-administration may require adjustment of cyclosporine dose due to changes in red blood cell volume.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Overdose
Overdose can lead to polycythemia (excessive red blood cells), which may require phlebotomy. Monitor hemoglobin levels closely and manage symptomatically.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit outweighs potential risk to the fetus. It is unknown whether darbepoetin alfa is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months when stored as recommended. Refer to product specific labeling.
Availability
Hospitals, specialized clinics, retail pharmacies (with prescription)
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patent expired or nearing expiration for original innovator, generics available.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
